Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

May 29, 2024

Study Completion Date

May 29, 2028

Conditions

Bietti's Crystalline Dystrophy

Interventions

GENETIC

NGGT001

Safety and Effectiveness of subretinal injection of NGGT001 for treating crystalline retinal degeneration

Trial Locations (1)

Xiuju Chen, Xiamen

All Listed Sponsors

lead

Xiamen Ophthalmology Center Affiliated to Xiamen University

OTHER